Breast cancer stands as the most prevalent cancer in women globally, and contributes to the highest percentage of mortality due to cancer-related deaths in women. Paclitaxel (PTX) is heavily relied on as a frontline chemotherapy drug in breast cancer treatment, especially in advanced metastatic cancer. Generation of resistance to PTX often derails clinical management and adversely affects patient outcomes. Understanding the molecular mechanism of PTX resistance is necessary to device methods to aid in overcoming the resistance. Recent studies exploring the mechanism of development of PTX resistance have led to unveiling of a range novel therapeutic targets. PTX resistance pathways that involve major regulatory proteins/RNAs like RNF8/Twist/ROR1, TLR, ErbB3/ErbB2, BRCA1- IRIS, MENA, LIN9, MiRNA, FoxM1 and IRAK1 have expanded the complexity of resistance mechanisms, and brought newer insights into the development of drug targets. These resistance-related targets can be dealt with synthetic/natural therapeutics in combination with PTX. The present review encompasses the recent understanding of PTX resistance mechanisms in breast cancer and possible therapeutic combinations to overcome resistance.

乳腺癌是全球女性中最普遍的癌症，并且由于女性与癌症相关的死亡而导致死亡率最高。紫杉醇（PTX）在乳腺癌治疗中，尤其是在晚期转移性癌症中，被高度依赖作为一线化疗药物。对PTX产生抗药性通常会破坏临床管理，并不利地影响患者预后。了解PTX耐药性的分子机制对于设备方法以帮助克服耐药性是必不可少的。探索PTX耐药性发展机制的最新研究导致了一系列新型治疗靶标的出现。涉及主要调节蛋白/ RNA的PTX耐药途径，如RNF8 / Twist / ROR1，TLR，ErbB3 / ErbB2，BRCA1-IRIS，MENA，LIN9，MiRNA，FoxM1和IRAK1扩大了耐药机制的复杂性，并为药物靶标的开发带来了新的见解。这些与抗药性相关的靶点可以与PTX结合使用合成/天然疗法治疗。本综述涵盖了对乳腺癌中PTX耐药机制的最新了解以及克服耐药性的可能疗法组合。